Clinical trials: Cancer Disease Progression
Castration-resistant Prostate Cancer
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
- Trial name
- NCT06636123
- Testing
- Investigational Agent Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line…
- Trial name
- NCT00929240
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 63 sites in Brazil, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Pancreatic Cancer
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer
A randomised multicentre clinical phase IIIb trial for patients suffering from pancreatic adenocarcinoma receiving defined second or higher line chemotherapy and additionally parenteral nutrition (study arm A) or best supportive…
- Trial name
- PANUSCO (NCT01362582)
- Testing
- SMOF Kabiven
- Where
- 4 sites in Germany
- Volunteers
- 32 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
KLF4 Methylation, Epigenetic
KLF4 Epigenetic Modulation
The study investigates the epigenetic regulation of KLF4 during the progression from colorectal polyps to adenomas and carcinomas.
- Trial name
- POLYEP (NCT07901335)
- Where
- Italy
- Volunteers
- 170 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Progression Free Survival
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
- Trial name
- NCT03100955
- Testing
- cisplatin, etoposide, cisplatin, etoposide, apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qingdao University
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Brain Tumor
Disease Progression and Treatment-induced Alterations in Glioblastoma
Summary of scientific evidence and rationale of this project: Integrative molecular-genetic approaches have provided important insights in the biology of glioblastoma.
- Trial name
- NCT02152748
- Testing
- analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Bladder Cancer, NMIBC
Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter Study
This study investigates whether a patient's age affects the outcomes of Bacillus Calmette-Guérin (BCG) treatment for high-grade bladder cancer.
- Trial name
- IATREP_NMIBC (NCT07798479)
- Testing
- Intravesical Bcg
- Volunteers
- 64 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
The investigators propose to conduct a pilot feasibility study of single agent erlotinib in patients with metastatic EGFR mutant adenocarcinoma of the lung with up to one prior treatment with the sole purpose of characterizing…
- Conditions
- Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Trial name
- NCT02431169
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients
The search for clinically actionable alterations within the non-metastatic prostate cancer setting has been an overlooked issue so far.
- Trial name
- NCT06875297
- Testing
- FPG500
- Where
- Italy
- Volunteers
- 184 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Renal Cell Carcinoma
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint…
- Trial name
- NCT04987203
- Testing
- Tivozanib, Nivolumab
- Where
- 139 sites in United States, Argentina and 14 more
- Volunteers
- 343 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies selinexor in treating patients with prostate cancer that has spread to other parts of the body (metastatic), keeps growing even when the amount of testosterone in the body is reduced to very low levels…
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02215161
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer, Primary Peritoneal Carcinoma
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of…
- Trial name
- NCT00083928
- Testing
- Å6 subcutaneous injection
- Where
- 24 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ångstrom Pharmaceuticals
Metastatic Breast Cancer
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].
- Trial name
- VERU-024 (NCT05065411)
- Testing
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Where
- 30 sites in United States
- Volunteers
- 5 people
- Sponsor
- Veru Inc.
Advanced Non Small Cell Lung Cancer (NSCLC)
Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC
Non-small cell lung cancer (NSCLC) is a common and aggressive type of lung cancer often diagnosed at advanced stages, with limited treatment options and poor prognosis.
- Trial name
- ALA /NSCLC (NCT07574684)
- Testing
- Alpha Lipoic Acid 600mg
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
This is a Phase 1/2 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with Tergenpumatucel-L immunotherapy and Docetaxel to treat subjects with advanced…
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Trial name
- NCT02460367
- Testing
- Docetaxel, Tergenpumatucel-L, Indoximod
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- NewLink Genetics Corporation
Triple Negative Breast Neoplasms
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
This is a multicenter, open-label, randomized phase II trial evaluating the efficacy and safety of sacituzumab govitecan plus toripalimab versus toripalimab plus nab-paclitaxel in patients with previously untreated, unresectable…
- Trial name
- NCT07040644
- Testing
- Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.